Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA): Difference between revisions

From MicrobeWiki, the student-edited microbiology resource
No edit summary
Line 28: Line 28:
The glycopeptide antibiotics vancomycin and linezolid are two effective treatments, with each using a slightly different method of action.  Vancomycin works by preventing cell wall synthesis in any Gram-positive bacteria.  As outlined by the CDC, this drug has been deemed one of “last resort” based on its adverse effects on the kidneys and hearing.  Though resistance has been low in response to vancomycin (though it was originally discovered in 1958) some cases of vancomycin-intermediate S. aureus (VISA) and a handful of vancomycin-resistant S. aureus (VRSA) have been noted.  The use of avoparcin in agriculture is suspected to have contributed to the rise of resistance to this antibiotic.  Linezolid and the tetracylines, on the other hand, bind and prevent the 30S ribosomal subunit from binding the 50S subunit and initiating transcription.  Clindamycin preferentially binds the 50S subunit to illicit the same result.  This prevents S. aureus from synthesizing necessary proteins, which ultimately leads to cell death.  Resistance to linezolid has remained extremely low (<0.5%) in the United States.  
The glycopeptide antibiotics vancomycin and linezolid are two effective treatments, with each using a slightly different method of action.  Vancomycin works by preventing cell wall synthesis in any Gram-positive bacteria.  As outlined by the CDC, this drug has been deemed one of “last resort” based on its adverse effects on the kidneys and hearing.  Though resistance has been low in response to vancomycin (though it was originally discovered in 1958) some cases of vancomycin-intermediate S. aureus (VISA) and a handful of vancomycin-resistant S. aureus (VRSA) have been noted.  The use of avoparcin in agriculture is suspected to have contributed to the rise of resistance to this antibiotic.  Linezolid and the tetracylines, on the other hand, bind and prevent the 30S ribosomal subunit from binding the 50S subunit and initiating transcription.  Clindamycin preferentially binds the 50S subunit to illicit the same result.  This prevents S. aureus from synthesizing necessary proteins, which ultimately leads to cell death.  Resistance to linezolid has remained extremely low (<0.5%) in the United States.  
<br>
<br>
==Section==
==Section==


==Conclusion==
==Conclusion==

Revision as of 02:32, 14 April 2009

By: Tom Hardacker

Introduction


Staphylococcus aureus is a circular, anaerobic, Gram-positive bacterium that is prevalent in the nose and skin of most individuals. While the majority of individuals who are colonized by S. aureus are simply carriers, this organism can cause a wide array of illnesses. Infections can range from mild skin irritation to more serious conditions such as endocarditis (inflammation of the inner heart), meningitis, pneumonia and Toxic Shock Syndrome (TSS), among others. Infections by S. aureus can also be prevalent in post-surgical wounds and due to the overuse of antibiotics; certain strains of this organism have become resistant to common treatments. For these reasons, certain strains of this organism have become increasingly problematic in hospitals and healthcare settings, as well as the general community.

Methicillin-Resistant Staphylococcus aureus (MRSA) is a strain of S. aureus that exhibits resistance to the β-lactam antibiotic methicillin (as well as other β-lactams), a common treatment for these infections. MRSA infections can be classified into two major groups: Hospital-acquired MRSA (HA-MRSA) and Community-acquired MRSA (CA-MRSA). HA-MRSA is responsible for post-operative wound infections, or infections resulting from implanted devices such as catheters, that are acquired within the healthcare setting. Typically, patients infected with HA-MRSA are immune-compromised and the resulting infections are generally more invasive. CA-MRSA typically manifests itself as skin infections, such as pimples or boils, and is classified as being acquired outside of any type of healthcare setting. These infections are typically more serious than minor skin irritation and affect otherwise healthy individuals. This article will focus on the latter form of MRSA (an in-depth article regarding HA-MRSA can be found here).

Origins of MRSA


Methicillin was developed by the pharmaceutical company Beecham in 1959 in response to bacteria that were resistant to the drug Penicillin (namely S. aureus). Like Penicillin, and other β-lactam antibiotics that were later developed, Methicillin acts by inhibiting cell-wall synthesis in Gram-positive bacteria. This class of antibiotics binds to the transpeptidase enzyme (also called Penicillin Binding Proteins, or PBPs), which is used by bacteria to cross-link peptidoglycan layers in the cell wall. The β-lactams competitively inhibit these enzymes and prevent these bacteria from successfully undergoing cell division. This ultimately leads to cell death and is a very effective mechanism in dealing with Gram-positive infections. [Wiki Methicillin]

Methicillin was particularly effective upon its introduction into medical use because of its resistance against β-lactamases secreted by bacteria in order to protect against Penicillin. The presence of the ortho-dimethoxyphenyl group on Methicillin prevents enzymatic hydrolysis of the β-lactam ring. However, quickly after its introduction into clinical use, S. aureus began to show resistance to Methicillin. The mechanism of S. aureus resistance to Methicillin is very similar to the mechanism of resistance to Penicillin. Resistance hinges on the presence of the mecA gene in the chromosome. This gene encodes Penicillin Binding Protein 2A, which significantly decreases Methicillin’s affinity to bind to the PBP targets. The mecA gene is a part of the mobile element SCCmec and is easily transferred among S. aureus communities by means of plasmid transfer. [Powerpoint, Evolution of MRSA]

Spread of Infection and Pathology


S. aureus lives harmlessly in the mucous membranes of the nose on about 33% of the general population [#6-Staph Wiki]. When the organism is able to penetrate the skin or mucous barriers it can lead to infection. The most common methods of spread outside of a hospital setting include: contact with pus from an infection site, skin-to-skin contact or sharing towels, clothing or athletic equipment with an infected individual. The compound hyaluronidase, which is produced by S. aureus, destroys soft tissue and allows for entry into the body.

Once and infection has occurred, the first, most common symptom is a significant abscess on the epidermis. From this abscess, proteolytic enzymes produced by S. aureus enable it to disperse throughout the body and cause secondary infections. The organism is now able to cause pneumonia and also infection of the joints, bones and heart valves. CA-MRSA strains also produce enterotoxins, which can cause serious illnesses. These toxins can be the cause of certain forms of food poisoning, Staphylococcal Scalded Skin Syndrome (SSSS), and Toxic Shock Syndrome (TSS). SSSS is a rare disease that usually affects infants by the production of an exfoliative enterotoxin. TSS is the most widely known byproduct of CA-MRSA infections. Improper use of tampons has been the cause of the vast majority of TSS cases, as the tampon can create a nutrient-rich environment for S. aureus to live. Symptoms include hypotension, fever, rash and can lead to hepatic and renal dysfunction, membrane hyperemia and thrombocytopenia. [Pathology]

Diagnosis and Treatment


CA-MRSA is differentiated from HA-MRSA based on an individual’s exposure to healthcare settings. If the patient has not been hospitalized (typically, the timeframe for hospitalization is up to one year), does not have any catheters or dialysis, and has not been recently admitted into a nursing home, etc. then any MRSA infection is likely community-acquired [CDC]. On a microbiological level, CA-MRSA has been shown to be genetically different from HA-MRSA and the two strains can be differentiated based on lab cultures as well. These differences allow CA-MRSA to spread more easily among individuals and use skin infections as a more prevalent mechanism of infection.

Strategies for diagnosing and treating CA-MRSA with a focus on Skin and Soft Tissue Infections (SSTIs) are outlined by the Center for Disease Control (CDC). S. aureus skin infections are commonly mistaken for spider bites by patients, as they are similar in their appearance. Any condition that may potentially exist in conjunction (or as a result of) a MRSA infection, such as pneumonia, osteomyelitis, or septic arthritis, is also regarded as potentially resulting from CA-MRSA. If a physician suspects that an infection is the result of S. aureus then a culture will be taken to obtain a definite identification (a blood, urine or drainage sample may be taken depending on the type of infection). These cultures not only serve to make a definite diagnosis, but also to track individual strains of MRSA.

For furuncles, abscesses and septic joints, the primary treatment option is incision and drainage by a physician. In controlled trials, this method has been shown to be 90% effective in dealing with CA-MRSA infections. If the SSTI is progressing more rapidly, then a physician may choose to supplement the drainage of the wound with antimicrobial therapy (antibiotics, etc.). Depending upon the rate of methicillin-resistance in the MRSA colony (identified based on lab cultures) a reasonable first-line antibiotic approach would include anti-staphylococcal β-lactams and cephalosporin. Non-β-lactam antibiotics that are effective against MRSA (especially those with a high rate of methicillin-resistance within the colony) include clindamycin, the tetracyclines, trimethaprim-sulfamethoxazole (TMP-SFX), rifampin, and linezolid. The use of fluoroquinolones and macrolides is not recommended for MRSA treatment based on the rapid development of resistance to these drugs. Severe MRSA infections should be treated with intravenous antibiotics such as clindamycin, daptomycin, linezolid, quinopristin-dalfopristin, tigecycline and TMP-SFX. For the full list of diagnosis and treatment methods as outlined by the CDC, click here.

The glycopeptide antibiotics vancomycin and linezolid are two effective treatments, with each using a slightly different method of action. Vancomycin works by preventing cell wall synthesis in any Gram-positive bacteria. As outlined by the CDC, this drug has been deemed one of “last resort” based on its adverse effects on the kidneys and hearing. Though resistance has been low in response to vancomycin (though it was originally discovered in 1958) some cases of vancomycin-intermediate S. aureus (VISA) and a handful of vancomycin-resistant S. aureus (VRSA) have been noted. The use of avoparcin in agriculture is suspected to have contributed to the rise of resistance to this antibiotic. Linezolid and the tetracylines, on the other hand, bind and prevent the 30S ribosomal subunit from binding the 50S subunit and initiating transcription. Clindamycin preferentially binds the 50S subunit to illicit the same result. This prevents S. aureus from synthesizing necessary proteins, which ultimately leads to cell death. Resistance to linezolid has remained extremely low (<0.5%) in the United States.

Section

Section

Conclusion


Overall paper length should be 3,000 words, with at least 3 figures.

References

[Sample reference] Takai, K., Sugai, A., Itoh, T., and Horikoshi, K. "Palaeococcus ferrophilus gen. nov., sp. nov., a barophilic, hyperthermophilic archaeon from a deep-sea hydrothermal vent chimney". International Journal of Systematic and Evolutionary Microbiology. 2000. Volume 50. p. 489-500.

Edited by student of Joan Slonczewski for BIOL 238 Microbiology, 2009, Kenyon College.